Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcu

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing ---- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis ---- Company Announces Extension of Runway to 3Q 2025 As Part of Po...

Related Keywords

New Haven ,Connecticut ,United States ,Eric Watsky ,Hannah Deresiewicz ,Jorge Gaeta ,Twitter ,Stern Investor Relations Inc ,Linkedin ,Company Announces Extension Of Runway ,Program Lead For Rallybio ,Exchange Commission ,Rallybio Corporation Nasdaq ,Term Development ,Results Demonstrated ,Mean Reduction ,Low Volume Oncea Week Subcutaneous ,Differentiated Therapeutic ,Generalized Myasthenia ,Announces Extension ,Webcast Today ,Rallybio Corporation ,Term Development Plans ,Stephen Uden ,Chief Executive Officer ,Technology Incubation Program ,Quarterly Report ,Investor Relations ,